Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
By: Benjamin N. Luehrs Generic forum selection clauses in patent license agreements can prevent licensees from trying to invalidate licensed patents at the United States Patent and Trademark Office (USPTO). A recent Federal Circuit Opinion, [Read More…]
WHIPgroup obtained another patent allowance just by filing an Appeal Brief. The application relates to a medical shaft instrument having a force transmission element that provides torsional and axial rigidity. The Examiner had rejected the [Read More…]
By Patrick D. Duplessis These days it seems almost every article or news report about self-driving vehicles (SDVs) includes the prophecy that the automobile will soon resemble a “smartphone on wheels.” That oft-repeated phrase alludes [Read More…]
